Silence Therapeutics Share Price (SLN)

50.95 -0.05 (-0.10%) delayed: 8:40PM GMT
Bid price 49.10 Open price 0.00
Ask price 52.80 Prev close 50.95
High price 0.00 Spread 7.01%
Low price 0.00 Volume 0

Register now for FREE live Silence Therapeutics share prices, Silence Therapeutics stock quotes, charts, trades market news and much much more. Why not upgrade to a premium service and get Silence Therapeutics Level 2 Data, indepth research tools and investor commentary for Silence Therapeutics (SLN) and other London Stock Exchange equities.

Silence Therapeutics Share Price Chart

Advanced Charts >>

Register now for FREE Silence Therapeutics share price charts

Silence Therapeutics Share Price Information

Name Silence Therapeutics Epic SLN
Sector Pharmaceuticals & Biotechnology ISIN GB00B9GTXM62
Activites Silence Therapeutics plc (formerly SR Pharma plc, formerly Stanford Rook Holdings plc) develops a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using its enabling delivery systems, it has achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases. Index n/a

Silence Therapeutics Key Numbers

Latest Share Price (p) 50.95 Net Gearing (%) n/a
Market Capitalisation (£m) 36.25 Gross Gearing (%) n/a
Shares in issue (m) 71.07 Debt Ratio n/a
P/E Ratio -22.17 Debt-to-Equity Ratio n/a
Total dividends per share (p) n/a Assets / Equity Ratio n/a
Dividend Yield (%) 0.00 Price to book value n/a
Dividend cover (x) 0.00 ROCE (%) n/a
Earning per share (p) -2.30 EPS Growth (%) n/a
52 week high / low 206.00 / 49.50 DPS Growth (%) n/a

Silence Therapeutics Director Deals

Dec.Date Type Director Pos No. of Shares
03/08/2017 BUY Alistair Gray NED 3,848
31/07/2017 BUY Dr Andrew Richards CH 7,000
18/04/2016 BUY Ali Mortazavi RES 160,000
18/04/2016 BUY Dr Stephen Parker NED 6,478
28/11/2012 BUY Ali Mortazavi RES 2,400,000

More Silence Therapeutics Director Deals >>

Silence Therapeutics Company News

08:00 15/01/2019

Silence Therapeutics treatment granted orphan drug status in Europe

Silence Therapeutics, said its lead medicine candidate for rare iron overload disorders had been granted orphan drug designation by European authorities. The designation for candidate was issued by the Committee for Orphan Medicinal Products, the European Medicines Agency's committee responsible...

07:00 15/01/2019

SLN124 granted Orphan Drug Designation by EMA

RNS Number : 0750N Silence Therapeutics PLC 15 January 2019     SLN124 granted Orphan Drug Designation by EMA for the treatment of β -Thalassemia   January 15, 2019     LONDON, Silence Therapeutics, PLC (LON: SLN) ("Silence" or "the Company") a leader in...

08:10 09/01/2019

Silence Therapeutics CFO David Ellam stands down

RNA-based therapy developer Silence Therapeutics said chief financial officer David Ellam had stood down with immediate effect. Current head of financial planning and analysis, Rob Quinn, would serve as interim CFO while a replacement was found. 'On behalf of the board I would like to thank...

More Silence Therapeutics Company News >>

Register now for FREE Silence Therapeutics company news

Silence Therapeutics Share Price Discussions

more than 1 year ago

Silence Therapeutics (SLN)

SILENCE THERAPEUTICS plc ("Silence Therapeutics" or "the Group") INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2007 London, UK, 28 September 2007 - Silence Therapeutics plc (London LSE: SLN)...

more than 1 year ago

Silence Therapeutics (SLN)

Cant find original Should be good next week

Register now for FREE Silence Therapeutics share price discussions